SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform
IND filing for Celiac Disease Anticipated in Third Quarter 2022
Clinical Translation Supported by Existing Red Blood Cell-Based Manufacturing Capabilities and Preclinical Models Demonstrating Treg Mediated Tolerance
WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical translation of the company’s Tolerizing Antigen Carrier (TAC) platform in autoimmune diseases will be for celiac disease, a chronic autoimmune disorder that afflicts millions of patients and has no approved drug treatment. The company anticipates an IND filing in the third quarter of 2022. In preclinical models, SQZ™ TACs have demonstrated the ability to induce multi-mechanism antigen-specific tolerance relevant to many immune mediated disorders. The company’s celiac disease program may support expansion into additional autoimmune diseases.